Open AccessHow should we treat a patient with early Parkinson’s disease?
Author(s) -
Tsouli S.,
Konitsiotis S.
Publication year - 2010
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2010.02371.x
Subject(s) - medicine , levodopa , dopaminergic , parkinson's disease , dopamine , disease , degenerative disease , neuroscience , psychology
Summary Parkinson’s disease (PD) is characterised by the progressive degeneration of dopaminergic nigro‐striatal neurons and severe striatal dopaminergic deficiency, leading to bradykinesia. Levodopa was the first drug used for PD treatment and is still considered the most useful weapon for the control of PD symptoms. However, levodopa treatment induces motor complications, which is considered as a major problem as the disease progresses. Dopamine agonists, catechol‐ O ‐methyltransferase inhibitors and monoamine oxidase B inhibitors are some more recently developed drug categories which are expected to have a more favourable effect on motor complications. The choice of the best initial treatment in PD remains a controversial matter. Early therapeutic decisions in PD should balance the need for efficient short‐term symptom control against long‐term complication profile. The individualisation of the treatment seems to be the key for the best approach of early PD patients.